Protocol Ledger

NCT05168163 · Phase II · RECRUITING

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Interventional Phase II clinical trial protocol NCT05168163 sponsored by Academic and Community Cancer Research United in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-27 Enrollment: 122 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05168163
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)122 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05168163
Protocol FieldVerified Registry Value
NCT IdentifierNCT05168163
Consolidated Lead SponsorAcademic and Community Cancer Research United
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment122 participants (ESTIMATED)
Registered Start Date2022-05-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05168163
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Mayo Clinic FloridaJacksonville, FLOpen Hospital Dossier ->
Cleveland Clinic FloridaWeston, FLOpen Hospital Dossier ->
University of Chicago MedicineChicago, ILOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI